Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06060145
Other study ID # 20230922-4
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 16, 2023
Est. completion date January 13, 2024

Study information

Verified date October 2023
Source Zhejiang Chinese Medical University
Contact Lina Zhang, Ph.D
Phone +8618540103321
Email zhanglina@zcmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled human exposure crossover study, aims to explore the health benefits of indoor plants on cardiopulmonary system on adults.


Description:

The researchers will conduct a randomized cross-controlled trial involving 48 healthy adults in Hangzhou, China. These participants will be randomly assigned into two groups, each comprising 24 individuals. Each participant will undergo two separate exposures in an office setting: one exposure without any plants present, and another exposure with 34 to 38 potted plants. A washout period of at least 4 weeks will be implemented between the two exposures. Questionnaires, physical examinations and the collection of biological samples will be conducted prior to exposure and after exposure. In addition, the monitoring of negative air ion, air pollutants and noise exposure, as well as collection of environmental microbial samples, will be conducted on weekdays. Researchers will gather samples of blood, urine, nasal secretion, and exhaled breath condensate from participants.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date January 13, 2024
Est. primary completion date January 13, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Living in Hangzhou during the study period; - Non-smoking, no history of alcohol or drug abuse; - Staying indoors in daytime we required. Exclusion Criteria: - Current or ever smokers; - Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy; - Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension; - Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease; - Subjects with chronic disease, such as diabetes, chronic hepatitis, and kidney disease; - Subjects with a history of major surgery; - Medication use or dietary supplements intake in recent two months; - Unable to cooperate with follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Plants placed in an office environment
The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
Devoid of any plant presence in an office environment
Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Lina Zhang Zhejiang Chinese Medical University

Outcome

Type Measure Description Time frame Safety issue
Other C-reactive protein(CRP) We plan to measure serum concentrations of C-reactive protein(CRP) Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
Other Interleukin-6(IL-6) We plan to measure the serum concentrations of Interleukin-6 Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
Other Tumor necrosis factor-a(TNF-a) We plan to measure the serum concentrations of Tumor necrosis factor-a Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
Primary Forced Vital Capacity(FVC) We plan to measure forced vital capacity (FVC) of lung function. Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
Secondary Blood Pressure(BP) We plan to measure systolic blood pressure (SBP) and diastolic blood pressure (DBP). Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
Secondary Heart Rate Variability(HRV) We plan to measure Heart Rate Variability (HRV). Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
See also
  Status Clinical Trial Phase
Recruiting NCT05145192 - COSMED K5 Validation and Reliability Study N/A
Recruiting NCT02286297 - Pediatric Endotracheal Intubation During Resuscitation N/A
Completed NCT00719498 - Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study) Phase 3
Not yet recruiting NCT06092827 - Feasibility and Acceptability of Non Weight-bearing Physical Activity for People With Diabetic Foot Ulceration N/A
Recruiting NCT05678530 - Estimated VO2Max Validation
Recruiting NCT05869747 - Firefighter Collaborative Research Project N/A
Active, not recruiting NCT04833010 - Effects of Face Masks During Exercise N/A
Recruiting NCT03123536 - Use of Point-of-care Ultrasound in High Risk Surgical Patients N/A
Completed NCT05787353 - Cardiopulmonary Rehabilitation for Post-acute COVID-19 Symptoms N/A
Completed NCT05518136 - Evaluations of Cardiopulmonary Function and Motor Development of Congenital Heart Disease N/A